OKYO Pharma to Include Additional Analyses in Upcoming Dry Eye Disease Key Opinion Leader Event | NASDAQ:OKYO
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024.
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye
Borr Drilling, Aehr Test Systems, Airship AI Among Premarket Losers' Pack
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
OKYO Pharma Limited (NASDAQ:OKYO) announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophth
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating.
HC Wainwright & Co. Maintains Buy on OKYO Pharma, Raises Price Target to $7
HC Wainwright & Co. analyst Yi Chen maintains OKYO Pharma with a Buy and raises the price target from $6 to $7.
OKYO Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 366.67% HC Wainwright & Co. $6 → $7 Maintains Buy 01/08/2024 233.33% HC Wainwright & Co. $4 → $
Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and OKYO Pharma Limited Sponsored ADR (OKYO)
OKYO Pharma Gains After Positive Results From Phase 2 Dry Eye Disease Trial
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease Including Ocular Pain Relief in Its First-in-Human Phase 2 Trial of OK-101
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable ben
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data From Phase 2 Dry Eye Disease Trial
–Phase 2 OK-101 efficacy data to be released March 22nd, 2024--KOL Event to be held on April 9th, 2024 at 12 PM ET-London and New York, NY, March 21, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clini
OKYO Pharma to Release New and Comprehensive Data From Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
–Phase 2 OK-101 efficacy data to be released March 22, 2024-London and New York, NY, March 20, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovati
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAinos (NASDAQ:AIMD) stock moved upwards by 54.3% to $1.62 during Friday's after-market session. The company's market cap stands at $7.5 million. Aadi Bioscience (NASDAQ:AADI) shares rose 38.54%
VUZI, TCBP and MANU Among Pre-market Losers
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersSeaStar Medical Holding (NASDAQ:ICU) shares rose 27.9% to $1.1 during Monday's pre-market session. The company's market cap stands at $71.6 million. Aesthetic Medical Intl (NASDAQ:AIH) shares i
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index adding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) rose 0.4%.
Sector Update: Health Care
Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index adding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) rose 0.5%.
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain
OKYO Pharma (OKYO) shares rose briskly on Friday after the biopharmaceutical company said US regulators have cleared it to begin phase 2 testing of its OK-101 drug candidate to treat neuropathic corne
No Data